baber/WOPTO huggingface dataset:
Patent NZ-295573-A (NZ)
Title: Ectoparasite (flea) saliva proteins and apparatus to collect them
Inventor: FRANK GLENN R
IPC: C12N5/10
Filed: 1995-10-06
Abstract: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention includes a saliva protein collection apparatus capable of collecting ectoparasite saliva proteins substantially free of contaminating material. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.
Patent NZ-331915-A (NZ)
Title: Dynamic bandwidth allocation for a communication network
Inventor: HOU VICTOR T
IPC: H04L47/762
Filed: 1997-03-17
Abstract: Bandwidth is adaptively allocated in an upstream channel of a layered data communication network such as that used for carrying messages from a number of subscriber units (250, 252, . . . , 254) to a central controller (210), for example, to allow the subscriber units to send data for Internet access, videoconferencing, or voice communication. A running total of unallocated bandwidth (BWA(j)) is maintained in successive control intervals. A traffic count (C(i)) is determined for each subscriber unit by measuring the bandwidth which is used, for example, by counting the number of slots used in a control interval. The assigned bandwidth (B(i)) of the subscriber units is then adjusted when a ratio (K) of the traffic count to the assigned bandwidth is at or below a lower threshold (T1), and the running total of unallocated bandwidth is incremented by the decrease in the assigned bandwidth. The assigned bandwidth may be increased when a ratio (K) of the traffic count to the assigned bandwidth is at or above an upper threshold (T2) by distributing the unallocated bandwidth among the subscriber units. A subscriber unit hierarchy may be used to grant priority to selected users.
Patent NZ-336583-A (NZ)
Title: Method of suspending insoluble calcium salts in protein composition by adding a protein source and heating
Inventor: KNIGHTS RALPH J
IPC: A23L2/39
Filed: 1997-12-23
Abstract: This method is for forming a dry powder of insoluble calcium salts and protein from an aqueous composition.  The process results in a dry powder that can be reconstituted in water with an unexpected extended and beneficial suspension of the insoluble calcium salts in the aqueous composition.  The process comprises: a)	mixing a protein source with water, b)	blending an insoluble calcium salt with the agitated aqueous mixture at temperature of 110-195oF, and c)	drying the resulting mixture. The resulting dry powder can be reconstituted in water or other media to produce a suspension of the insoluble calcium salts with the beneficial feature that the calcium salts do not sediment or separate.
Patent NZ-337712-A (NZ)
Title: Sealed unit LED lamp for vehicle
Inventor: REINBACH MARTIN CARL FRIEDRICH
IPC: B60Q3/02
Filed: 1999-09-08
Abstract: he LEDs 41 to 43 for a vehicle lamp are supported on a circuit board 40 and inserted into a housing 25 including the lens of the lamp unit 10.  A backing member 50 is then adhesively secured to the rear of the housing and detachably supports the cable 70 supplying power to the LEDs.  The insulation of the cable conductors  71 is bared to a position behind the rear of the backing member so that the adhesive covers the bared conductors at the rear of the backing member to seal the backing member against the housing to form a sealed enclosure.
Patent NZ-338053-A (NZ)
Title: Courtesy light for garage door operated for a period depending on opener power supply frequency
Inventor: FITZGIBBON JAMES J
IPC: H05B37/02
Filed: 1999-09-27
Abstract: A door operator includes an AC powered electric motor and a transmission between the motor and the door for movement of the door on rotation of the motor.  A circuit detects the AC line voltage and frequency of the alternating current supplied to the motor, and a controller sets the operational parameters of a worklight in dependence on the detected line current frequency.  For example, United States systems at 60Hz have the worklight turned on for 4.5 minutes, whereas New Zealand systems at 50Hz might only require that the worklight be turned on for 2.5 minutes.
Patent NZ-500253-A (NZ)
Title: Osteoprotegerin binding proteins and receptors
Inventor: BOYLE WILLIAM J
IPC: C12N15/11
Filed: 1998-04-15
Abstract: A polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.  Receptors for osteoprotegerin binding proteins are also described. The receptors, and agonists and antagonists thereof, may be used to treat bone diseases
Patent NZ-501376-A (NZ)
Title: 4-(6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)-2-piperazine-carboxamide derivatives useful for inhibition of farnesyl protein transferase
Inventor: COOPER ALAN B
IPC: A61P35/00
Filed: 1998-06-15
Abstract: A 4-(6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)-2-piperazine-carboxamide derivative or a pharmaceutically acceptable salt or solvate thereof has the formula (1.0) wherein: a is N or NO-; Ra, Rb, Re and Rd are independently halo, alkyl or alkoxy provided that at least one, but not more than two of Ra, Rb, Re and Rd are H; the dotted line (---) is an optional double bond; R is H, -C(O)-CH2-O-(CH2)2-O-CH3, -S(O)2R1, -S(O)2NR1R2, -C(O)R1 or -C(O)NR1R2; R1 and R2 are independently H, optionally substituted alkyl, aryl, arylalkyl, triazolyl, 2-, 3- or 4-pyridyl or pyridyl N-oxide, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or heterocycloalkyl; Re and Rf are independently H or optionally substituted alkyl, alkyloxyalkyl, aryl, arylalkyl, triazolyl, alkyloxyalkyloxyalkyl, 2-, 3- or 4-pyridyl or pyridyl N-oxide, imidazole, cycloalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkyl or Re is H, alkyl or aryl and Rf is -(CH2)n-R15 or Re and Rf together with the nitrogen to which they are bound form an optionally substituted piperidine or pyrrolidine; n is 0 to 8; R15 is C(O)NH2, -SO2NH2, benzodioxoxlyl or optionally substituted aryl, heteroaryl, cycloalkyl or heterocycloalkyl or R15 is -C(A)-B NR16R17; B is OH or NH2; A is NH, O, NOH or NCN; R16 is H or alkyl; R17 is H, alkyl, SO2CH3 or C(O)NH2 and Rh is H or =O; provided that when Rh is H and Rb and Rd are both H then Re is H and Rf is a group of formula (2) and heteroaryl  alone or as part of heteroarylalkyl is a 5 or 6 membered heterocyclic having at least one heteroatom N, S or O. A pharmaceutical composition thereof is useful for inhibiting the abnormal growth of cells such as tumor cells expressing an activated ras oncogene specifically pancreatic tumor cells, lung cancer cells, myeloid leukemia tumor cells, thyroid follicular tumor cells, myelodysplastic tumor cells, epidermal carcinoma tumor cells, bladder carcinoma tumor cells, or colon tumor cells.
Patent NZ-502964-A (NZ)
Title: Expression of gonadotropins in dictyostelium
Inventor: BLAAUW MIEKE
IPC: A61K38/00
Filed: 1998-09-02
Abstract: Gonadotropins may be obtained by heterologous expression in a Dictyosteliym host.  These gonadotropins are characterized in that the subunits are covalently linked. A strain of Dictyosteliym is transformed with a recombinant plasmid vector comprising a DNA sequence encoding the gonadotropin genes or mutated genes under control of Dictyosteliym regulatory sequences.  The recombinant strains are cultured under conditions to allow expression of the DNA sequence.  Gonadotropin mutants with super agonistic or antagonistic properties may be selected by determining the receptor binding/signal transduction ratio of the expressed protein and isolating clones with a ratio deviating from the ratio determined for wild type gonadotropins.
Patent NZ-503852-A (NZ)
Title: Death associated kinase containing ankyrin repeats (DAKAR)
Inventor: BIRD TIMOTHY A
IPC: C12N1/15
Filed: 1999-08-04
Abstract: Described are purified and isolated DAKAR (death-associated kinase containing ankyrin repeat) polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of the polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses of the above.
Patent NZ-505897-A (NZ)
Title: Method for producing (-)cis-3-hydroxy-1-methyl-4-(2,4,6- trimethoxyphenyl)-piperidine
Inventor: BREIPOHL GERHARD
IPC: C07D405/04
Filed: 1998-12-18
Abstract: The  process  to  (-)cis-3-hydroxy-1-methyl-4-(2,4,6- trimethoxyphenyl)piperidine   (formula    (II))    comprises converting 1-methlpiperidin-4-one into the hydrobromide. Reacting  the  1methylpiperidin-4-one  hydrobromide   in   a suitable  solvent  in  the temperature range  from  0oC-30oC with  bromine  to give 3(R,S)-bromo-1-methyl-4-oxopiperidine hydrobromide.   Reacting  this  intermediate   directly   by addition  of 0.8-1 equivalent of 1,3,5-trimethoxybenzene  to the  reaction  at  0oC-30oC  to give  3(R,S)-bromo-1-methyl- (2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydropyridine hydrobromide  (formula (VI)) and if appropriate additionally adding  acetic  anhydride to remove any  water  of  reaction formed. Then  either isolating compound (VI) as a solid by  stirring the  reaction solution into a suitable organic  solvent  and subsequently reacting the resulting product with  water  and by  stirring at 50oC-100oC to give3(R,S)-hydroxy-1-methyl-4- (2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydropyridine (compound   (VII))   or   treating  the   reaction   mixture containing the compound of formula (VI) directly with  water and  reacting  by  stirring at 50oC-100oC to  give  compound (VII)   or   by  cooling  the  reaction  mixture  comprising compound  (VI) diluting with further water and adjusting  to pH>12  at  0oC-30oC  by  addition of  aqueous  alkali,  with compound  (VII) precipitating, filtering off  the  resulting crude product. Then  catalytically  hydrogenating  the  resulting  compound (VII)  in  a suitable solvent or mixtures of these  using  a suitable  catalyst  to give the racemic 3,4-cis  alcohol  of formula VII. Then  obtaining the enantiomerically pure cis  alcohol  (II) from  the  compound (VII) by a known process  by  resolution using suitable auxiliary reagents. Compound (II) obtained by the above process can be used  for the preparation of flavopiridol.
Patent NZ-510628-A (NZ)
Title: Use of a tetracycline derivative for reducing the risk of cataract formation in a mammal
Inventor: RYAN MARIA EMANUEL
IPC: A61K31/00
Filed: 1999-09-28
Abstract: A method of reducing the risk of cataract development in mammals comprising administering a tetracycline derivative.
Patent NZ-516895-A (NZ)
Title: Raffinate resistant bacterial strains, methods of preparing the same and use thereof in fermentation proceses for L-lysine production
Inventor: LIAW HUNGMING J
IPC: C12R1/15
Filed: 2000-08-01
Abstract: A method for the production of an improved raffinate-resistant amino acid producing bacterial strain B comprises: (a)subjecting a parental bacterial strain A to mutagenesis; (b)contacting the mutagenized parental strain A with a medium containing at least about 1% raffinate bacterial strain B; (c)selecting a raffinate-resistant bacterial strain B; and (d)determining amino acid production of the resistant bacterial strain B. preferably the parental bacterial strain is selected form Corynebacterium sp., Brevibacterium sp., Escherichia coli and Bacillus sp. and the amino acid produced is L-lysine. Also described are L-lysine producing bacterial strains and process for the production of amino acids.
Patent NZ-518660-A (NZ)
Title: Method for extracting soluble or membrane associated intracellular proteins
Inventor: JOHANSEN CLAUS LINDVALD
IPC: C12N15/81
Filed: 2000-11-24
Abstract: A method for releasing a soluble or membrane associated intracellular protein of interest from a bacterial or fungal cell comprising: a) providing a bacterial or fungal cell containing the protein of interest; b) releasing the protein from the cell by contacting the cell with a membrane extracting composition comprising a quaternary ammonium compound; and c) causing the protein to be released from the cell under conditions sufficient for the specific release of the protein in a soluble form; in which the protein has a higher specific activity than when it has been extracted by mechanical means. Also covered are proteins extracted using this method.
Patent NZ-521117-A (NZ)
Title: Method of treating or inhibiting colonic polyps
Inventor: FROST PHILIP
IPC: A61K31/4706
Filed: 2001-03-06
Abstract: Use of a cyanoquinoline compound of formula (1) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or inhibiting colonic polyps is disclosed, wherein R1, R2, R3, R4, X, Y, and n are as defined in the specification,.
Patent NZ-521844-A (NZ)
Title: Tamandarin and didemnin analogs having deoxo-proline residue or dehydro-proline residue and methods of making and use thereof
Inventor: JOULLIE MADELEINE M
IPC: A61P31/04
Filed: 2001-04-09
Abstract: Disclosed herein are didemnin analogs, including tamandarin analogs and didemnin and tamandarin analogs that have a deoxo-proline residue or a dehydro-proline residue in their structure. These analogs are useful as anti-cancer agents and for other purposes. Methods of making these analogs and methods of using them as inhibitors of protein synthesis, cell growth, and tumorigenesis and as enhancers of apoptosis are also disclosed.
Patent NZ-521899-A (NZ)
Title: Sub-calibre projectile and method of making such a projectile
Inventor: JOHANSSON BERTIL
IPC: F42B14/06
Filed: 2001-03-30
Abstract: A composed projectile for subcalibre projectile comprising a sabot (8), a projectile (7) and a driving speculum (13), whereby said composed projectile comprises a projectile made of a metal material, preferably having a high density, and that the length of the composed projectile (6) is not substantially longer than the projectile (7), as well as a cartridge comprising such a composed projectile.
Patent NZ-530113-A (NZ)
Title: Method for inhibiting bone resorption in a unit dosage form
Inventor: DAIFOTIS ANASTASIA G
IPC: A61K31/66
Filed: 2000-08-28
Abstract: Disclosed is the use of a bisphosphonate in the manufacture of a medicament for inhibiting bone resorption in a mammal. The medicament is adapted for oral administration in a unit dosage form which comprises from about 3.5mg to about 200mg of the bisphosphonate, on an acid active basis, according to a continuous schedule having a dosage interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing and twice-monthly dosing. (62) Divided Out of 508507
Patent NZ-530377-A (NZ)
Title: System and method for modelling pricing of securities such as expected risk, rate of return and default loss
Inventor: REDMAYNE JOHN
IPC: G06Q40/00
Filed: 2003-12-24
Abstract: A computer system is for measuring the credit risk of an asset, estimating the covariance of returns of securities, estimating the correlation of securities, applying an option theoretic model of a firm and relating a price or value of a plurality of securities associated with an underlying asset, the rate of return on the securities and the risk attributes of the securities is disclosed. Specifically when system relates a price or value of a plurality of securities associated with an underlying asset, the rate of return on the securities and the risk attributes of the securities, the system comprises: a computer-readable memory; a risk analysis unit; a risk pricing unit; a financial modelling unit and a user interface device operative to exchange information with a user. The risk analysis unit is operative to designate that a priced risk factor incorporated in the risk premium for each security is the volatility of returns, measured over discrete time. The risk pricing unit is operative to: determine a risk premium incorporated in the rate of return for each security; and designate that the price per unit of this risk factor is the same for two or more of the securities. The financial modelling unit is operative to define a model comprising data representing relationships between the risk premiums determined for each security and store the model in the computer-readable memory.
Patent NZ-531462-A (NZ)
Title: Food product and process
Inventor: HUSBAND ALAN JAMES
IPC: A23L1/30
Filed: 2001-01-22
Abstract: Food products and pharmaceutical preparations containing one or more isoflavones are described. In particular, the invention relates to highly purified, crystalline isoflavones having an agreeable taste, texture and mouth-feel when formulated in food products and pharmaceutical preparations, and methods for the production of the highly purified, crystalline isoflavones. (62) Divided Out of 519944
Patent NZ-536319-A (NZ)
Title: Secreted and transmembrane polypeptides and nucleic acids encoding the same
Inventor: EATON DAN L
Filed: 2000-03-01
Abstract: An isolated nucleic acid that encodes a polypeptide designated PRO6030 having the amino acid sequence in Figure 38 (SEQ ID NO:72) is described. The polypeptide is capable of inducing fetal hemoglobin in erythroblastic cells. Preferably the nucleic acid has the sequence of Figure 37 (SEQ ID NO:71) or that deposited under ATCC accession number 479-PTA. Also described are host cells, antibodies, vectors and methods of producing the polypeptide.
Patent NZ-536941-A (NZ)
Title: Improved warp connection means for anchor
Inventor: EDER RAYMOND NEILL
Filed: 2005-09-27
Abstract: An anchor means (1) having an anchor head H with flukes for engagement with the sea-bed, a shaft (2) extends outwardly from the head, and a warp connection means (10) for connection to a warp W. The warp connection means engages the shaft in two alternative modes. In the first mode the warp connection is retained in a restricted portion (5) of the shaft remote from the head. In the second mode the connection is longitudinally movable towards and away from the head via a guide passage (7). The restricted portion is formed by a projecting bar (8) and the warp connection means has a reduced dimension portion (12) so that the connection may be moved between the first mode which provides a relatively permanent mooring arrangement and the second mode which provides a trippable mooring arrangement. The warp connection means comprises a shackle and the reduced dimension portion comprises a depression on one or both sides of the shackle. (61) Addition to 230110
Patent NZ-536981-A (NZ)
Title: A method of improving the growth performance of an animal
Inventor: STROM ALAN DAVID GREVE
IPC: A23K50/70
Filed: 2002-05-24
Abstract: Disclosed is the use of one or more anti-inflammatory agents in the manufacture of a medicament used to improve the growth performance of an animal. Also disclosed is the use of a compound or composition which increases or supplements endogenous anti-inflammatory agent levels in the manufacture of a medicament used to improve the growth performance of an animal, wherein growth performance is enhanced relative to the growth performance of an animal which has not been administered said compound or composition.
Patent NZ-537670-A (NZ)
Title: Process for introducing a 1,2-double bond in 3-oxo-4-azasteroid compounds
Inventor: SCHARER NORBERT
IPC: C07J/
Filed: 2003-07-02
Abstract: A process for preparing 17beta-substituted 4-asaandrost-1-en-3-one compounds of the general formula (I) so that a compound of formula (III) with 1, 2-double bond in 3-oxo-4-azasteroids is formed.
Patent NZ-551090-A (NZ)
Title: Collapsible projection screen systems
Inventor: CREEL SILAS
Filed: 2004-05-12
Abstract: A collapsible projection screen system mountable on or at a moveable carriage 10, the system comprising: a flexible projection screen 16 movable between a collapsed position and an erect position in which the screen 16 is supported by a support arrangement 14 15, and in addition to the support arrangement 14 15, a screen tensioning mechanism 64 40 operable on the screen in the erect position to provide a generally flat screen surface.
Patent NZ-554742-A (NZ)
Title: Dairy product and process
Inventor: YE AIQIAN
IPC: A23L29/275
Filed: 2007-04-24
Abstract: Disclosed is a method for preparing a gel comprising: a) mixing oil or fat with an aqueous medium by homogenisation to form an oil-in-water emulsion; and b) heating the mixture to 50 degrees Celsius to 200 degrees Celsius for a period sufficient to form an emulsion gel wherein the mixture comprises 1.0 % to 3.8 % (w/w) of a protein that forms a heat-set gel, and 5 to 18 % (w/w) oil or fat or a mixture of oil and fat.
Patent NZ-554829-A (NZ)
Title: Dissolution device to simulate gastro-intestinal tract and analyze release rate of active agent in a pharmaceutical
Inventor: BURKE MATTHEW D
Filed: 2005-11-03
Abstract: An apparatus and method are provided for analyzing the release of active agent(s) from pharmaceutical and pharmaceutical-like products. The apparatus and method provide for more accurate simulation of the conditions in the GI tract including forces that are applied to the dosage form.
Patent NZ-561462-A (NZ)
Title: Novel 5,7-disubstituted [1,3]thiazolo[4,5-D]pyrimidin-2(3H)-one derivatives
Inventor: NORDVALL GUNNAR
IPC: A61K31/519
Filed: 2006-04-03
Abstract: Provided is compound of formula (I), which is an antagonist of CX3CR1 receptor and useful for the treatment or prophylaxis of neurodegenerative disorders, rheumatoid arthritis and pulmonary diseases such as COPD, asthma or pain.
Patent NZ-562658-A (NZ)
Title: Improvements in and relating to soil treatments using fine particulate elemental sulphur
Inventor: HALL ROBERT HAMILTON
IPC: C05G3/90
Filed: 2007-10-18
Abstract: Disclosed is a soil treatment composition in granular form as a fertiliser for application on to or into soil, said soil treatment composition including at least one active soil treatment component, said active soil treatment component including particulate elemental sulphur, said particulate elemental sulphur being finely ground to particles having a reactive surface area in the granule in the region of 1280 cm2 per gram. In addition to the particulate elemental sulphur the composition can also include another component from a list including: (a) Bentonite; (b) A solvent; (c) Urea; (d) Triple Super Phosphate; (e) Lime; (f) A urease inhibitor; (g) A nitrification inhibitor and (h) Particulate Reactive Rock Phosphate. Urea is preferably used as a binding and dispersing agent for the fine elemental sulphur particles as it is agronomically valuable and acts as a binding and dispersing agent for the fine elemental sulphur particles. These granules can be produced with dispersants such as bentonite where required.
Patent NZ-565178-A (NZ)
Title: 3-substituted-2-(arylalkyl)-1-azabicycloalkanes and methods of use thereof
Inventor: MAZUROV ANATOLY A
IPC: C07D487/08
Filed: 2004-02-20
Abstract: Disclosed are radiolabeled compounds of formula I, wherein the substituents are as defined in the specification. The compounds are useful for the diagnosis of central nervous system disorders.